ArticleCancer cell international2025
A multi-center study for colorectal cancer early detection in high-risk disease patients using cell-free fragmentomics assay.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic Accuracy of Blood-Based cfDNA/ctDNA Tests for Colorectal Cancer-A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Navigating the molecular landscape: integrated multiomics liquid biopsy for biomarker discovery in early detection and monitoring of colorectal cancer.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundEarly detection of colorectal cancer (CRC) is crucial for improving patient survival. This innovative multi-center study aims to develop a non-invasive blood-based assay using cell-free DNA (cfDNA) fragmentomics to differentiate CRC from advanced colorectal adenomas and non-cancerous colorectal and other digestive diseases.
methodsA total of 167 CRC patients and 227 with benign colorectal conditions were divided into training and validation cohorts (1:1 ratio). Plasma cfDNA underwent Low-depth whole-genome sequencing to profile three fragmentomics features, which were integrated into a stacked ensemble model. The model was validated on 69 CRC patients and 96 benign controls, with an additional cohort of 31 advanced adenoma patients included to assess its performance in differentiating advanced adenomas from benign cases.
resultsThe model achieved an AUC of 0.926, with sensitivity of 91.3% and specificity of 82.3% in validation. Sensitivities were consistently high across CRC stages (I: 94.4%, II: 86.4%, III: 91.3%, IV: 100%). Notably, the model demonstrated exceptional accuracy in distinguishing advanced adenomas from benign cases, achieving an AUC of 0.846 and sensitivity of 67.7%, outperforming traditional blood tests.
conclusionsThis multi-center study underscores a significant advancement in liquid biopsy technology, offering a highly accurate and non-invasive approach for early CRC detection and differentiation of advanced colorectal adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.